ANI Pharmaceuticals (NASDAQ:ANIP) Issues FY 2025 Earnings Guidance

ANI Pharmaceuticals (NASDAQ:ANIP) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 6.120-6.490 for the period, compared to the consensus earnings per share estimate of 5.560. The company issued revenue guidance of $756.0 million-$776.0 million, compared to the consensus revenue estimate of $724.9 million.

ANI Pharmaceuticals Trading Down 5.5 %

Shares of NASDAQ:ANIP opened at $58.46 on Tuesday. The company has a market capitalization of $1.23 billion, a P/E ratio of -106.29 and a beta of 0.74. ANI Pharmaceuticals has a 1 year low of $52.50 and a 1 year high of $70.81. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. The business’s 50 day simple moving average is $57.23 and its 200 day simple moving average is $58.13.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Leerink Partnrs upgraded ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. StockNews.com cut ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday. Leerink Partners assumed coverage on ANI Pharmaceuticals in a research note on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 price target for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research note on Monday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, ANI Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $77.71.

Insider Activity

In other ANI Pharmaceuticals news, SVP Krista Davis sold 1,000 shares of the business’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $60.00, for a total transaction of $60,000.00. Following the sale, the senior vice president now owns 49,059 shares of the company’s stock, valued at $2,943,540. The trade was a 2.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Stephen P. Carey sold 7,500 shares of the business’s stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total transaction of $418,425.00. Following the transaction, the chief financial officer now owns 154,468 shares of the company’s stock, valued at $8,617,769.72. This trade represents a 4.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 10,300 shares of company stock worth $584,009 in the last three months. Company insiders own 12.70% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.